{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:53:07Z","timestamp":1761443587690,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001469","name":"Singapore General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004327","name":"SingHealth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcyt.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T23:39:03Z","timestamp":1678059543000},"page":"510-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-2590","authenticated-orcid":false,"given":"Yeh-ching","family":"Linn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-9355","authenticated-orcid":false,"given":"Kirubavathy","family":"Sundar Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chew-Yen","family":"Phang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-2554","authenticated-orcid":false,"given":"Manesh","family":"Chittezhath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickey","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jcyt.2023.02.003_bib0002","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jcyt.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2023.02.003_bib0004","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2023.02.003_bib0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"10.1016\/j.jcyt.2023.02.003_bib0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41409-019-0614-1","article-title":"Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction","volume":"54","author":"O'Reilly","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jcyt.2023.02.003_bib0007","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood advances"},{"issue":"12","key":"10.1016\/j.jcyt.2023.02.003_bib0008","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/hdy.2013.27","article-title":"Population-specific recombination sites within the human MHC region","volume":"111","author":"Lam","year":"2013","journal-title":"Heredity"},{"issue":"8","key":"10.1016\/j.jcyt.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"242","key":"10.1016\/j.jcyt.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Science translational medicine"},{"issue":"22","key":"10.1016\/j.jcyt.2023.02.003_bib0012","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood advances"},{"key":"10.1016\/j.jcyt.2023.02.003_bib0013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2019.06.007","article-title":"A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance","volume":"205","author":"Luah","year":"2019","journal-title":"Clin Immunol"},{"issue":"9331","key":"10.1016\/j.jcyt.2023.02.003_bib0014","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.jcyt.2023.02.003_bib0015","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\"Mini\" bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood advances"},{"issue":"10","key":"10.1016\/j.jcyt.2023.02.003_bib0016","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2013.07.015","article-title":"CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome","volume":"19","author":"Sukdolak","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2023.02.003_bib0017","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10875-021-01205-1","article-title":"Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients","volume":"42","author":"Schulze Lammers","year":"2022","journal-title":"J Clin Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:47:58Z","timestamp":1761443278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1465324923000397"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.02.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}